Lv3
260 积分 2025-10-01 加入
Pharmacokinetics-Driven Optimization of 4(3H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension
15小时前
待确认
Pharmacokinetics-Driven Optimization of 4(3H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension
15小时前
已完结
Epimedium and its chemical constituents in cancer treatment: A comprehensive review of traditional applications, antitumor effects, pharmacokinetics, delivery systems, and toxicology
16小时前
已完结
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects
16小时前
已完结
TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats
16小时前
已完结
Frequency and Zero-Point Vibrational Energy Scale Factors for Double-Hybrid Density Functionals (and Other Selected Methods): Can Anharmonic Force Fields Be Avoided?
5天前
已完结
Understanding the molecular basis of NO-releasing β-cyclodextrin derivatives and ferulic acid co-delivery for advanced therapeutics: A theoretical study
6天前
已完结
Chemical constituents of radix Actinidia chinensis planch by UPLC–QTOF–MS
7天前
已完结
Acute hemodynamic effects of TPN171H in pulmonary arterial hypertension: a randomized, controlled, phase 2a trial
8天前
已完结
Rational design of Gi-biased CB1 agonist with reduced side effects
9天前
已完结
皖公网安备34019202002308
